Gilead, Foresite Take Pardes Biosciences Public In $250M SPAC Deal

  • Pardes Biosciences Inc, an early-stage biopharmaceutical company, and FS Development Corp. II FSII, a Foresite Capital sponsored SPAC, entered into a definitive merger agreement.
  • Pardes Biosciences was founded at the beginning of 2020 by Uri Lopatin, a former Gilead executive who co-founded and served as CMO of Assembly Biosciences. 
  • Despite the thin online presence, Foresite is giving Pardes the $175 million they raised for the SPAC, plus another $75 million in private funding from Gilead Sciences Inc GILDRA Capital Management, and Frazier Life Sciences.
  • The company anticipates initiating clinical trials later this year and plans to study PBI-0451 for prophylaxis and treatment of SARS-CoV-2 infections.
  • The U.S. recently announced a $3.2 billion program to accelerate the development of antivirals for future pandemics. And Pardes' lead program, PBI-0451, is an oral antiviral drug candidate designed to inhibit an essential viral protein causing COVID-19.
  • Price Action: FSII shares are up 0.62% at $9.94 during the market session on the last check Tuesday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechNewsHealth CareFinancingOfferingsIPOsGeneralBriefsSPACs Attack
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!